LD 952 LR 1530(01)
An Act To Ensure Access to Opiate Addiction Treatment in Maine
Preliminary Fiscal Impact Statement for Original Bill
Sponsor: Sen. Woodsome of York
Committee: Health and Human Services
Fiscal Note Required: Yes
Preliminary Fiscal Impact Statement
FY 2017-18 FY 2018-19 Projections  FY 2019-20 Projections  FY 2020-21
Net Cost (Savings)
General Fund $1,016,715 $954,483 $954,483 $954,483
General Fund $1,016,715 $954,483 $954,483 $954,483
Federal Expenditures Fund $1,784,905 $1,722,137 $1,722,137 $1,722,137
Federal Expenditures Fund $1,784,905 $1,722,137 $1,722,137 $1,722,137
Fiscal Detail and Notes
The Department of Health and Human Services will require General Fund appropriations of $1,016,715 in fiscal year 2017-18 and $954,483 in fiscal year 2018-19 to increase the MaineCare reimbursement rate for outpatient opioid treatment to $80 per week and for a 3rd-party consultant to conduct a rate study regarding reimbursement to outpatient opioid treatment providers. Federal Expenditures Fund allocations will also be required for the FMAP match.

The bill also authorizes opioid treatment programs to operate without maintaining a pharmacist in charge but requires opioid treatment programs to enter into a written agreement with a licensed pharmacist to serve as a consultant to the opioid treatment program and it authorizes registered professional nurses, certified nurse practitioners and licensed practical nurses to dispense opioid medication for substance abuse treatment purposes to patients in an opioid treatment program. Any impact from these changes is unable to be determined at this time.